Abstracts tagged "Lupus and belimumab"

Abstract Number: 2650 • 2018 ACR/ARHP Annual Meeting
Efficacy, Safety, and Predictor of Response to Belimumab in a Large Nationwide Cohort Study of Patients with Active Systemic Lupus Erythematosus
Luca Iaccarino¹, Francesca Saccon¹, Alessandro Mathieu², Matteo Piga³, Angela Ceribelli⁴, Carlo Selmi⁵, Paolo Cardinaletti⁶, Armando Gabrielli⁷, Andrea Di Matteo⁸, Rossella De Angelis⁹, Paola Faggioli¹⁰, Antonella Laria¹¹, Micaela Fredi¹², Francesca Regola¹³, Angela Tincani¹², Laura Andreoli¹⁴, Giulia Pazzola¹⁵, Carlo Salvarani¹⁵, Francesco Puppo¹⁶, Ottavia Magnani¹⁶, Marcella Prete¹⁷, Elisa Gremese¹⁸, Maria Gerosa¹⁹, Tania Ubiali²⁰, Enrica Bozzolo²¹, Valentina Canti²¹, Vito Racanelli¹⁷, Fabrizio Conti²², Fulvia Ceccarelli²³, Elena Bartoloni²⁴, Roberto Gerli²⁵, Antonio Lobasso²⁶, Amato de Paulis²⁷, Ginevra De Marchi²⁸, Salvatore De Vita²⁹, Alessandra Bortoluzzi³⁰, Marcello Govoni³⁰, Francesco Benvenuti³¹, Margherita Zen³², Marta Mosca³³, Chiara Tani³⁴, Maurizio Rossini³⁵, Giovanni Orsolini³⁵, Salvatore Scarpato³⁶, Ernico Brunetta³⁷, Aurora Zumbo³⁸, Giacomo Tanti³⁹ and Andrea Doria⁴⁰, ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²University of Cagliari, Cagliari, Italy, ³Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ⁴Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, ⁵Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ⁶University of Ancona, Ancona, Italy, ⁷Univeristy of Ancona, Ancona, Italy, ⁸Polytechnic University of Marche, Rheumatology Clinic, Jesi, Italy, ⁹Polytechnic University of Marche, Rheumatology Clinic, jesi, Italy, ¹⁰Hospital of Legnano, Legnano, Italy, ¹¹Hospital of Magenta, Magenta, Italy, ¹²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹³University of Brescia, Brescia, Italy, ¹⁴Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹⁵University of Reggio Emilia, Reggio Emilia, Italy, ¹⁶University of Genova, Genova, Italy, ¹⁷University of Bari, Bari, Italy, ¹⁸Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ¹⁹Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ²⁰Istituto Gaetano Pini, University of Milano, Milano, Italy, ²¹Hospital San Raffaele, Milano, Italy, ²²Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ²³UO Complessa Reumatologia, Policlinico Umberto I Università Sapienza di Roma, Rome, Italy, ²⁴Rheumatology Unit, University of Perugia, Perugia, Italy, ²⁵Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ²⁶University Federico II of Napoli, Napoli, Italy, ²⁷Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy, ²⁸Hospital/University of Udine, Udine, Italy, ²⁹Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ³⁰UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ³¹University of Padova, Padova, Italy, ³²Division of Rheumatology, University of Padova, Padova, Italy, ³³Rheumatology Unit, University of Pisa, Pisa, Italy, ³⁴Univeristy of Pisa, Pisa, Italy, ³⁵Rheumatology Unit, University of Verona, Verona, Italy, ³⁶Hospital of Salerno, Salerno, Italy, ³⁷Humanitas Hospital, Milano, Italy, ³⁸Humnaitas Hospital, Milano, Italy, ³⁹Catholic University of the sacred hearth, Roma, Italy, ⁴⁰University and Azienda Ospedaliera of Padova, Padova, Italy
Background/Purpose: To investigate effectiveness, safety, and predictors of response to belimumab in patients with active SLE in clinical practice setting. Methods: Four hundred and one…
Abstract Number: 780 • 2016 ACR/ARHP Annual Meeting
Belimumab Use in African-American Patients in an U.S. Academic Medical Center
Paloma Alejandro¹, Anjani Pillarisetty² and Christopher E. Collins³, ¹Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, ²Internal Medicine, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, ³MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC
Background/Purpose: Belimumab is an anti-BAFF monoclonal antibody approved for the treatment of auto-antibody positive patients with SLE. In two large phase 3 clinical trials, belimumab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].